Biomarker HLA-DOA for sepsis-related diseases and application of biomarker HLA-DOA

Through the detection of HLA-DOA biomarker, the problem of early diagnosis of sepsis was solved, the early warning and treatment timing of sepsis were improved, and the survival rate of patients was significantly improved.

CN118979103APending Publication Date: 2024-11-19CHENGDU CELENOV BIOTECH CO LTD
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202410977780.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-19
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The prior art is difficult to diagnose sepsis early before organ dysfunction, resulting in delayed intervention time and affecting patient survival.

Method used

Using HLA-DOA or its active fragments as biomarkers, products and systems for early diagnosis of sepsis, risk assessment, immune status assessment, prognosis prediction and treatment regimen selection are provided.

Benefits of technology

HLA-DOA has better diagnostic efficacy, can distinguish patients with infection and sepsis, and early warning and diagnosis, which improves the treatment timing of sepsis and significantly improves the survival rate of patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118979103A_ABST
    Figure CN118979103A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of molecular diagnosis, and relates to a sepsis-related disease biomarker HLA-DOA and application thereof. The invention provides application of HLA-DOA or active fragments and functional fragments thereof in preparation of products for early diagnosis, risk assessment, immune state assessment, prognosis prediction and / or treatment scheme selection of sepsis-related diseases of an object. The biomarker HLA-DOA is identified by utilizing a plurality of sequencing analysis means, detecting blood samples of clinical infected patients and tracking clinical outcomes of the infected patients. The HLA-DOA is used for identifying common infection and sepsis and has high diagnostic efficiency, and ROC analysis shows that the AUC value of the HLA-DOA reaches 0.8954. Therefore, the sepsis biomarker provided by the invention has great significance on clinical early-stage sepsis diagnosis and also has good application in the in-vitro diagnostic reagent industry.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of molecular diagnosis, and specifically relates to the use of HLA-DOA as a biomarker for sepsis-related diseases in the preparation of products for early diagnosis, risk assessment, immune status assessment, prognosis prediction and / or treatment regimen selection of sepsis-related diseases. Background Art

[0002] At present, the diagnosis of sepsis mainly relies on clinical indicators, and the diagnostic criteria are "infection + SOFA ≥ 2". The SOFA score, or Sequential Organ Failure Assessment (SOFA), is a scoring system that assesses the severity and prognosis of critically ill patients based on clinical blood biochemical tests and clinical indicators. The higher the score, the more severe the condition. The serum marker currently used to assist in the diagnosis of sepsis is procalcitonin (PCT). However, an increase in PCT only indicates infection, and it has a good distinction between infected and non-infected patients, but it is difficult to distinguish between common infections and sepsis. In summary, due to the lack of sepsis-specific molecular markers, it is difficult for clinicians to make early diagnosis and identification before the onset of organ dysfunction (SOFA ≥ 2). Early intervention is a universal principle for the treatment and management of sepsis. For every hour of delay in treatment, the patient's survival rate will decrease by about 7.6% (Ferrer, R., et al. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. American journal of respiratory and critical care medicine 180, 861-866 (2009).; Kumar, A., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Critical care medicine 34, 1589-1596 (2006).). If a new molecular marker of sepsis can be found, the occurrence of sepsis can be warned and diagnosed through its test results before organ dysfunction occurs, and the time window for intervention in sepsis can be advanced, so that patients can receive more timely treatment. Summary of the invention

[0003] The object of the present invention is to provide biomarkers for sepsis-related diseases and their use in preparing products for early diagnosis, risk assessment, immune status assessment, prognosis prediction and / or treatment regimen selection of sepsis-related diseases in subjects.

[0004] Another object of the present invention is to provide products and systems for early diagnosis of sepsis-related diseases, risk assessment, immune status assessment, prognosis prediction and / or treatment regimen selection for a subject.

[0005] In order to solve the above technical problems and achieve the above objectives, the present invention provides the following technical solutions:

[0006] In a first aspect, the present invention provides the use of HLA-DOA or an active fragment or functional fragment thereof as a biomarker in the preparation of a product for early diagnosis, risk assessment, immune status assessment, prognosis prediction and / or treatment regimen selection of a subject's sepsis-related disease.

[0007] In some embodiments, the early diagnosis, risk assessment, immune status assessment, prognosis prediction and / or treatment regimen selection of the subject's sepsis-related disease comprises: determining the HLA-DOA level in a sample from the subject, and comparing the HLA-DOA level in the sample with a reference value to perform early diagnosis, risk assessment, immune status assessment, prognosis prediction and / or treatment regimen selection for the subject.

[0008] In a second aspect, the present invention provides a product for early diagnosis of sepsis-related diseases, risk assessment, immune status assessment, prognosis prediction and / or treatment regimen selection in a subject, characterized in that the product comprises a reagent, a kit and / or a detection device for detecting the HLA-DOA level in a sample from the subject.

[0009] In some embodiments, the sepsis-related disease includes sepsis, severe sepsis or septic shock; the sepsis-related disease is SOFA<2 in the early stage; and / or the subject is diagnosed with infection or suspected of infection.

[0010] In some embodiments, the HLA-DOA is selected from at least one of an HLA-DOA gene, an HLA-DOA mRNA, a cDNA of an HLA-DOA mRNA, or an HLA-DOA protein.

[0011] In some embodiments, the sample is from a subject's body fluids, cells, tissues, metabolites, and / or excreta.

[0012] In some preferred embodiments, the sample is from a body fluid of a subject, and the body fluid is selected from at least one of blood, plasma, extracellular fluid, tissue fluid, lymph fluid, or cerebrospinal fluid.

[0013] In some more preferred embodiments, the sample is from the subject's blood, preferably peripheral blood.

[0014] In some embodiments, the kit comprises:

[0015] (i) detecting an effective amount of a reagent for detecting HLA-DOA in a sample from a subject;

[0016] (ii) optionally, at least one substance selected from the following group: container or packaging, auxiliary agent, solution, buffer, negative control substance, positive control substance or instruction.

[0017] In some embodiments, the reagent comprises at least one of the following: a primer, a probe, an antibody, a biochip or a small molecule compound that specifically detects HLA-DOA.

[0018] In some embodiments, the agent is directly or indirectly labeled with a detectable label, wherein the detectable label is selected from at least one of the following: a radioisotope, a fluorescent group, a chemiluminescent moiety, an enzyme, an enzyme substrate, an enzyme cofactor, an enzyme inhibitor, a dye, a metal ion or a ligand.

[0019] In some embodiments, the kit includes at least one of a Western blot kit, an enzyme-linked immunosorbent assay kit, a radioimmunoassay kit, a radial immunodiffusion kit, a two-dimensional two-phase immunodiffusion kit, a rocket immunoelectrophoresis kit, an immunohistochemistry staining kit, an immunoprecipitation assay kit, a complement fixation assay kit, a fluorescence-activated cell sorting kit, an aptamer chip kit, a microarray kit, a protein chip kit, a qPCR kit, or a flow cytometry analysis kit.

[0020] In some embodiments, the detection device is selected from at least one of the following:

[0021] Detection equipment used for real-time quantitative reverse transcription PCR, biochip detection, Southern blotting, Northern blotting, in situ hybridization, immunofluorescence or immunohistochemistry.

[0022] In a third aspect, the present invention provides a system for early diagnosis, risk assessment, immune status assessment, prognosis prediction and / or treatment regimen selection of a subject's sepsis-related disease, characterized in that the system comprises:

[0023] (1) a first device for collecting and / or receiving data on HLA-DOA levels in a sample from a subject;

[0024] (2) A second device for analyzing the data to perform early diagnosis of sepsis-related diseases, risk assessment, immune status assessment, prognosis prediction and / or treatment plan selection for the subject.

[0025] In some embodiments, the first device comprises the product of the second aspect;

[0026] In some embodiments, the analyzing comprises comparing the level of HLA-DOA in the sample to a reference value.

[0027] In a fourth aspect, the present invention provides a method for early diagnosis, risk assessment, immune status assessment, prognosis prediction and / or treatment regimen selection of a subject's sepsis-related disease, the method comprising:

[0028] 1) collecting and / or processing a sample from a subject to make the HLA-DOA level detectable;

[0029] 2) using any of the aforementioned products or systems to detect the HLA-DOA level of the subject;

[0030] 3) Comparing the HLA-DOA level of the subject with a reference value, thereby performing early diagnosis, risk assessment, immune status assessment, prognosis prediction and / or treatment regimen selection for the subject.

[0031] In some embodiments, the early stage of the sepsis-related disease is SOFA<2.

[0032] In some embodiments, the subject has a confirmed infection or a suspected infection.

[0033] In some embodiments, the sepsis-related disease comprises sepsis, severe sepsis, or septic shock.

[0034] In some embodiments, the sample is from a subject's bodily fluids, cells, tissues, metabolites, and / or excreta.

[0035] In some preferred embodiments, the sample is from a body fluid of a subject, selected from at least one of the following:

[0036] Blood, plasma, extracellular fluid, tissue fluid, lymph or cerebrospinal fluid.

[0037] In some more preferred embodiments, the sample is from the subject's blood, preferably peripheral blood.

[0038] In some embodiments, the HLA-DOA level includes the HLA-DOA mRNA molecule level, the cDNA molecule level of the HLA-DOA mRNA and / or the HLA-DOA protein molecule level.

[0039] The present invention uses a variety of sequencing analysis methods, blood sample detection of clinically infected patients, and tracking of the clinical outcomes of these infected patients to identify that the two molecules of HLA-DOA show obvious expression changes in the early stage of sepsis, which can distinguish between infected and non-infected patients, and can distinguish between common infections and patients who eventually progress to sepsis. It is expected to be used as a sepsis immune marker for early diagnosis of sepsis, immune status assessment and prognosis judgment. HLA-DOA has a good diagnostic efficacy. ROC analysis shows that its AUC value for distinguishing common infections from sepsis is 0.8954, which exceeds the diagnostic efficacy of PCT, a commonly used clinical indicator. Therefore, the sepsis biomarker provided by the present invention is of great significance for the diagnosis of early clinical sepsis, and also has good application in the in vitro diagnostic reagent industry. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] Figure 1 The figure shows the level of HLA-DOA mRNA detected by digital PCR in peripheral blood immune cells of healthy volunteers (normal control), patients with common infections and patients with sepsis.

[0041] Figure 2 The results of ROC curve analysis of HLA-DOA mRNA levels in the common infection group and the sepsis group are shown.

[0042] Figure 3 The results of ROC curve analysis of HLA-DOA expression and clinical outcome information of 176 sepsis patients in the sequencing data set E-MTAB-7581 of the Biostudies database are shown.

[0043] Figure 4 The results of Kaplan-Meier survival curve analysis of HLA-DOA expression and clinical outcome information of 479 sepsis patients in the sequencing data set GSE65682 of the GEO database are shown.

[0044] Figure 5 The flow cytometric analysis of HLA-DOA protein expression in peripheral blood immune cells of mice in the control group and the sepsis group is shown. DETAILED DESCRIPTION

[0045] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as commonly used in the field to which the present invention belongs. For the purpose of interpreting this specification, the following definitions will apply, and where appropriate, terms used in the singular will also include the plural form, and vice versa.

[0046] Unless the context clearly dictates otherwise, the expressions "a", "an" and "an" as used herein include plural references. For example, reference to "a cell" includes a plurality of such cells and equivalents thereof known to those skilled in the art, and so forth.

[0047] As used herein, the term "about" means a range of ±20% of the value that follows. In some embodiments, the term "about" means a range of ±10% of the value that follows. In some embodiments, the term "about" means a range of ±5% of the value that follows.

[0048] Numerical ranges used herein should be understood to include all numbers within the range. For example, a range of 1 to 20 should be understood to include any number, combination of numbers, or subrange from the following group: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.

[0049] As used herein, the term "comprises" or "comprising" means "including but not limited to". The term is intended to be open-ended to specify the presence of any stated features, elements, integers, steps, or components, but not to preclude the presence or addition of one or more other features, elements, integers, steps, components, or groups thereof. Thus, the term "comprising" encompasses the more restrictive terms "consisting of" and "consisting essentially of".

[0050] As used herein, the terms "optional," "either," "any," or "either" mean that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and where it does not.

[0051] As used herein, the term "and / or" should be understood to mean any one of the optional items or a combination of any two or more of the optional items.

[0052] As used in this article, the terms "first" and "second" are used for descriptive purposes only to distinguish different description objects, and should not be understood as indicating or implying relative importance or implicitly indicating the number of technical features indicated, nor should they be understood as indicating an order or connection relationship, etc.

[0053] As used herein, the term "sepsis-related disease" refers to a class of diseases of life-threatening organ dysfunction caused by a disordered host response to infection, including, but not limited to, sepsis, septic shock, and severe sepsis. In some preferred embodiments, the sepsis-related disease is sepsis. The specific definition and diagnostic criteria of sepsis can be found in Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315 (8): 801-810. doi: 10.1001 / jama.2016.0287.

[0054] As used herein, the term "subject" refers to an animal, preferably a mammal, and more typically a human being. The subject investigated by the method of the present invention is preferably a subject with a suspected infection. The term "suspected infection" as used herein refers to clinical parameters, signs and / or symptoms of an infection exhibited by a subject. Therefore, a subject according to the present invention is typically a subject suffering from an infection or suspected of having an infection, more typically a subject visiting an emergency department.

[0055] As used herein, the term "infection" refers to a pathological process caused by pathogenic or potential pathogenic bodies / pathogens, organisms and / or microorganisms invading normal sterile tissues or liquids, and preferably relates to infections of bacteria, viruses, fungi and / or parasites. Therefore, infection can be bacterial infection, viral infection and / or fungal infection. Infection can be local or systemic infection. For purposes of the present invention, viral infection can be considered as an infection of a microorganism.

[0056] As used herein, unless otherwise specified or clearly determined, the term "HLA-DOA" may include HLA-DOA genes, HLA-DOA mRNA, cDNA of HLA-DOA mRNA and / or HLA-DOA proteins. HLA-DOA belongs to the α chain family of HLA class II molecules, which binds to the β chain encoded by the HLA-DOB gene to form HLA-DO heterodimers, which play a role in the antigen presentation process of B cells, regulate the function of HLA-DM molecules, and thus affect the stability of peptide-MHC class II molecule complexes and antigen presentation efficiency. HLA-DOA is expressed in a variety of tissues, especially in secondary lymphoid organs such as lymph nodes and spleen.

[0057] As used herein, the term "reference value" refers to a standard value for comparison with the level (content or activity) of a biomarker in a sample, and the reference value can be calculated according to the average level of the biomarker determined in samples isolated from a plurality of healthy individuals or individuals with sepsis. Typically, the reference value is given as a range of reference values. Therefore, the terms "reference value" and "range of reference values" used herein are defined to have the same meaning.

[0058] The reference value may be a negative reference value established from a healthy person or a common infected person. For example, a decrease in the HLA-DOA level relative to the negative reference value generally indicates that the patient suffers from a sepsis-related disease, or is at risk of developing a sepsis-related disease, or is at risk of immunosuppression, or is at risk of a poor prognosis. The reference value may also be a positive reference value established from a patient with sepsis, or a series of positive reference values ​​established from sepsis patients with different degrees of progression. HLA-DOA that is comparable to the positive reference value generally indicates the corresponding degree of sepsis progression, immune status, or prognosis.

[0059] As used herein, the term "reduced" can refer to a decrease in the level (e.g., expression or activity) of a detected biomarker by 5%, 10%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more compared to a reference value.

[0060] As used herein, the terms "reagent", "detection reagent" or "reagent for detecting HLA-DOA levels" are used interchangeably and refer to substances that are specific for HLA-DOA molecules and can be used to directly or indirectly detect the presence and / or content of HLA-DOA genes, mRNA, cDNA and proteins. According to the sequence of the HLA-DOA molecule, a person of ordinary skill in the art can prepare reagents specific for the HLA-DOA molecule based on conventional means or obtain them commercially. For example, the detection reagents that can be used in the present invention include, but are not limited to: antibodies (preferably monoclonal antibodies), probes, gene chips, PCR primers, gRNA, etc. that have detection specificity for HLA-DOA molecules. In addition, in order to facilitate detection, the detection reagents disclosed in the present invention may also be accompanied by a detectable label, and the detectable label includes, but is not limited to: radioactive isotopes, fluorophores, chemiluminescent moieties, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, dyes, metal ions, ligands (such as biotin or haptens), etc. The detection reagent disclosed herein may be present in a solution, fixed on a carrier (such as a substrate, an adsorbent), or in other conventional forms in the art, as long as the form of existence is suitable for detecting HLA-DOA in a biological sample. For example, when the detection reagent of the present invention is a nucleotide probe, it may be present in the form of a biochip (or "microarray").

[0061] As used herein, the terms "product" or "test product" are used interchangeably, meaning a combination of substances or reagents specific for HLA-DOA, or their combined use, auxiliary use, and the like. According to the needs of the detection method used, an appropriate HLA-DOA detection substance can be selected and made into a product suitable for the detection method used, such as a kit. A person of ordinary skill in the art can adjust and change the detection method and the reagents contained in the product according to actual conditions and needs. The product disclosed herein may also include other reagents clinically used for early diagnosis of sepsis-related diseases in subjects, risk assessment, immune status assessment, prognosis prediction (or assessment, judgment) and / or treatment regimen selection, to assist or verify the results obtained by detecting HLA-DOA. A person of ordinary skill in the art can make routine selections according to specific needs.

[0062] To make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with the examples. If the specific conditions are not specified in the examples, they are carried out according to the normal conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified for all reagents or instruments, they are all conventional products that can be purchased commercially. In order to better illustrate the present invention, numerous specific details are given in the specific embodiments below. The specific embodiments described herein are only used to explain the present invention and are not intended to constitute any limitation of the present invention. In addition, in the following description, the description of known structures and technologies is omitted to avoid unnecessary confusion of the concept of the present invention. Such structures and technologies are also described in many publications, such as "Molecular Cloning Experiment Guide (Fourth Edition)" (Cold Spring Harbor Laboratory Science Press), Ausubel, FM et al., Current Protocols in Molecular Biology, Greene Publishing Assoc. and Wiley-Interscience.

[0063] Example 1. Validation of the clinical diagnostic efficacy of HLA-DOA for distinguishing common infections from sepsis

[0064] (1) Extraction of total RNA

[0065] 40 patients with common infection, 11 patients with sepsis and 20 healthy controls were enrolled from West China Hospital of Sichuan University. Their peripheral blood was collected in K3EDTA blood anticoagulation tubes and lysed overnight (-80℃) or on ice for 30 minutes by adding an appropriate volume of Trizol in an enzyme-free environment; the lysed blood was thawed at room temperature, mixed by inversion, and allowed to stand at room temperature for 10 minutes. 1 / 5 of the sample volume (about 200μL) of chloroform was added to it, vortexed for 30 seconds, and left for 5 minutes. Pink was observed in the lower layer and colorless in the upper layer. Centrifuged in a 4℃ centrifuge: 12000g, 20 minutes; after centrifugation, the sample was clearly divided into three layers: pink miscellaneous proteins were in the lower layer, white DNA was in the middle layer, and RNA was in the colorless water layer at the top. Carefully pipette RNA into a new enzyme-free tube; add an equal volume of isopropanol, mix it with RNA, and transfer it to -20℃ together, waiting for RNA precipitation (about 1 hour to 2 hours). After centrifugation at 12000g for 10 minutes at 4°C, a white block of RNA precipitate can be seen at the bottom of the tube. Remove the supernatant, add the prepared DEPC (alcohol: DEPC = 3:1) to the precipitate to resuspend the RNA, and centrifuge in a 4°C centrifuge, 12000g, 5 minutes, repeat twice. After removing the supernatant, air-dry the RNA in a fume hood, and when the precipitate becomes colorless and transparent, add 30μL of enzyme-free water, mix thoroughly, and measure the RNA concentration using the Thermo Scientific Nanodrop.

[0066] (2) Reverse transcription

[0067] Removal of genomic DNA: Add 1 μg of qualified RNA to the following reaction system, gently pipette to mix, then transfer the prepared reaction mixture to a metal bath and react at 42°C for 2 minutes.

[0068] Table 1. Genome removal reaction system

[0069] Reagents Volume (μL) 5×gDNA Eraser Buffer 2 gDNA Eraser 1 <![CDATA[RNase Free ddH2O]]> 7-X Total RNA Template (1μg) XμL Total volume 10

[0070] Take out the mixture after the reaction from the metal bath, and prepare the mRNA reverse transcription reaction system according to the composition in the table below. After completion, put the mixture into the PCR instrument for reverse transcription. The reverse transcription program is: 37℃, 15 minutes; 85℃, 2 minutes; 4℃ insulation.

[0071] Table 2. Reverse transcription reaction system

[0072] Reagents Volume (μL) 5×Prime Script Buffer 2for(real time) 4 <![CDATA[RNase Free ddH2O]]> 4 RT Primer Mix 1 Prime Script RT Enzyme Mix I 1 Reaction to remove genomic DNA 10 Total volume 20

[0073] (3) Digital PCR detection

[0074] After reverse transcription is completed, the obtained cDNA concentration is diluted to about 0.2 ng / μL RNA equivalent, and the ddPCR reaction system of the gene to be tested is prepared: 1 μL cDNA template, QX200 from Bio-rad TM ddPCR TM 10 μL of enzyme premix reaction solution, 0.8 μL of primers (0.4 μL each for forward and reverse primers) and water were added to make up to 20 μL system. The primer sequences are: HLA-DOA-F: CATCTGCATCGTGGACAACA (SEQ ID NO: 1); HLA-DOA-R: AAATGGTCAGGCTGGGAAT (SEQ ID NO: 2).

[0075] The absolute copy number of HLA-DOA mRNA was detected using Bio-Rad's QX200 ddPCR instrument according to its instructions. The QX200 ddPCR system mainly uses microfluidics technology to achieve large-scale partitioning of samples to be tested. Each sample will be prepared into about 20,000 nano-scale droplet molecules before testing.

[0076] The test results were displayed in a scatter plot, and the differences between the groups were compared using one-way ANOVA. The Mann-Whitney u test was used to compare the common infection group and the sepsis group (p<0.0001). The results showed that compared with the normal control, the HLA-DOA expression in the common infection patients was significantly reduced, and the HLA-DOA expression in the sepsis patients was the lowest ( Figure 1 ). Receiver operating characteristic curve (ROC) analysis was performed on the HLA-DOA mRNA expression levels in the common infection group and the sepsis group. The sensitivity was used as the ordinate to represent the true positive rate, and 1-specificity was used as the abscissa to represent the false positive rate. The ROC curve was plotted. The area under the curve (AUC) reflects the value of the diagnostic test. The larger the area, the closer it is to 1.0, the better the diagnostic efficacy and the higher the accuracy; the closer it is to 0.5, the lower the diagnostic efficacy; when it is equal to 0.5, it has no diagnostic value. The results of ROC analysis showed that the AUC of the common infection group compared with the sepsis group was 0.8954, indicating that the HLA-DOA mRNA level has a high diagnostic efficacy in distinguishing sepsis from common infections ( Figure 2 )

[0077] Example 2. Receiver operating curve and Kaplan-Meier survival curve to evaluate the predictive efficacy of HLA-DOA for the prognosis of patients with sepsis

[0078] The present invention analyzes the sequencing data set E-MTAB-7581 (https: / / www.ebi.ac.uk / biostudies / arrayexpress / studies?query=E-MTAB-7581) of the public database Biostudies database. The data set contains 176 patients with sepsis, and the mRNA expression of HLA-DOA and clinical outcome information of the patients are collected for ROC analysis. The process of drawing the ROC curve is to calculate the sensitivity, specificity and false positive rate (1-specificity) of all cutoff points. With sensitivity as the ordinate to represent the true positive rate, 1-specificity as the abscissa to represent the false positive rate, the ROC curve is drawn, and the area under the curve (Area Under Curve, AUC) is calculated. On the ROC curve, the point in the upper left corner of the curve is often selected as the best cutoff value point, and the corresponding sensitivity and specificity are relatively optimal at this time. The results of ROC analysis showed that the area under the curve (AUC) was 0.76, the sensitivity was 0.817, the specificity was 0.606, and the optimal cutoff value was 5.421, which had good accuracy and clinical application value ( Figure 3 ).

[0079] The present invention analyzes 479 sepsis patients with clinical prognosis information in the public database GEO database GSE65682 data set (https: / / www.ncbi.nlm.nih.gov / geo / query / acc.cgi?acc=GSE65682). The mRNA expression of HLA-DOA and clinical outcome information of the patients were collected, and Kaplan-Meier survival curve analysis was performed. The Kaplan-Meier survival curve is mainly used to analyze the impact of a single factor on survival, to estimate the patient survival rate and to draw a survival curve. The survival curve is a continuous step curve drawn with the survival time as the horizontal axis and the survival rate as the vertical axis to illustrate the relationship between survival time and survival rate. In the fields of medicine, biology, etc., Kaplan-Meier survival curves are often used to evaluate the prognosis of diseases, treatment effects, etc. The Kaplan-Meier survival curve was used to analyze the prognostic value of HLA-DOA for sepsis patients in the GSE65682 data set. The results showed that the expression of HLA-DOA was correlated with the survival rate of sepsis patients (p=0.074) ( Figure 4 ).

[0080] Example 3. Flow cytometry to verify the difference in HLA-DOA protein expression

[0081] (1) Construction of animal model:

[0082] All wild-type C57 mice (SPF grade) of the present invention were purchased from Beijing Huafukang Biotechnology Co., Ltd. The age range of the mice was 7-8 weeks, and the weight range was 20g-25g. The purchased mice were all adaptively raised for one week in the Experimental Animal Center Building of the Frontier Medical Research Center of West China Hospital, Sichuan University. The breeding room was well ventilated, the humidity was 50%-60%, and the room temperature was controlled at about 26°C. The night and day were alternately 12 hours each day. The mice were fed with standard feed and had free drinking water; the experiment was carried out after one week of adaptive feeding.

[0083] Construction of severe infection (sepsis) model (denoted as Critical group): 6-8 week old C57 mice were selected and anesthetized with sodium pentobarbital. The abdominal skin of the mice was prepared with a shaver. After disinfection with iodine, the mice were opened under sterile conditions, i.e. a small incision was made 0.5 cm to the left of the midline of the abdomen. The cecum was separated and gently removed with surgical forceps (curved forceps), and then ligated with sterile No. 4 thread at 0.75 cm from the blind end, followed by piercing with an 18-gauge thick needle once, and then the cecum was returned to the abdominal cavity, the muscle layer and outer skin layer of the mice were sutured, and after disinfection with iodine, the mice were returned to the breeding cage for observation.

[0084] The healthy sham operation group (denoted as Sham group) served as the control: the operation before laparotomy was consistent with the sepsis model, only the cecum was found after laparotomy, but it was not ligated or punctured, and was gently placed back into the abdominal cavity. The muscle layer and outer skin layer of the mice were sutured, and the mice were disinfected with iodine and returned to the breeding cage for observation.

[0085] All mice were immediately injected subcutaneously with 800 μL of normal saline for fluid rewarming after modeling, and 20 mg / kg of ciprofloxacin was injected intramuscularly in the thigh.

[0086] (2) Flow cytometry detection of HLA-DOA expression:

[0087] (a) The sepsis model (Sepsis) was established according to the above animal modeling method, and the sham operation group (Sham) was used as the healthy control.

[0088] (b) Collect 50ul of mouse peripheral blood into a K3EDTA blood anticoagulant tube and mix by inversion.

[0089] (c) Add flow cytometry antibodies for all genes to be tested according to the instructions (usually 2.5 μL / test): CD45 (Brand: BD Pharmingen TM , Catalog No.: 557659); HLA-DOA antibody (Brand: ThermoFisher-Invitrogen, Catalog No.: AB_2552186).

[0090] (d) Add 450 μL of 1X FACs hemolysin to the counting tube and incubate at room temperature (20°C) in the dark for 15 minutes to fully lyse the red blood cells.

[0091] (e) For flow cytometry detection, the sample does not need to be washed. Dapi is added 5 minutes before the flow cytometer detection to perform cell live and dead staining, and then the sample can be loaded onto the instrument.

[0092] (f) Result analysis

[0093] The FAC file downloaded from the flow cytometer was analyzed using Fiowjo 10.0. The results are as follows: Figure 5 As shown in the data, compared with the healthy control group, the HLA-DOA protein level in the peripheral blood immune cells of the sepsis group was significantly reduced, which suggests that the detection of HLA-DOA protein levels in peripheral blood immune cells can also be used for the diagnosis of sepsis.

[0094] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.

Claims

1. Use of HLA-DOA or its active fragments or functional fragments as biomarkers in the preparation of products for early diagnosis, risk assessment, immune status assessment, prognosis prediction and / or treatment regimen selection of subjects with sepsis-related diseases.

2. The use according to claim 1, characterized in that The early diagnosis, risk assessment, immune status assessment, prognosis prediction and / or treatment regimen selection of the subject's sepsis-related disease comprises: determining the HLA-DOA level in a sample from the subject, and comparing the HLA-DOA level in the sample with a reference value to perform early diagnosis, risk assessment, immune status assessment, prognosis prediction and / or treatment regimen selection for the subject.

3. A product for early diagnosis, risk assessment, immune status assessment, prognosis prediction and / or treatment regimen selection of a subject's sepsis-related disease, characterized in that: The articles of manufacture comprise reagents, kits and / or detection devices for detecting the level of HLA-DOA in a sample from a subject.

4. The use according to claim 1 or the product according to claim 3, characterized in that: The sepsis-related diseases include sepsis, severe sepsis or septic shock; the sepsis-related diseases are characterized by SOFA<2 in the early stage; and / or the subject is diagnosed with infection or suspected of infection.

5. The use according to claim 1 or the product according to claim 3, characterized in that: The HLA-DOA is selected from at least one of HLA-DOA gene, HLA-DOA mRNA, cDNA of HLA-DOA mRNA or HLA-DOA protein.

6. The product according to claim 3, characterized in that The sample is from the subject's body fluids, cells, tissues, metabolites and / or excreta; Preferably, the sample is from a body fluid of a subject, and the body fluid is selected from at least one of blood, plasma, extracellular fluid, tissue fluid, lymph fluid or cerebrospinal fluid; More preferably, the sample is from the subject's blood; More preferably, the sample is from peripheral blood of a subject.

7. The product according to any one of claims 3 to 6, characterized in that: The kit comprises: (i) detecting an effective amount of a reagent for detecting HLA-DOA in a sample from a subject; (ii) optionally, at least one substance selected from the group consisting of: a container or packaging, an adjuvant, a solution, a buffer, a negative control, a positive control, or instructions; and / or, the reagent comprises at least one of the following: a primer, a probe, an antibody, a biochip or a small molecule compound for specific detection of HLA-DOA; Preferably, the reagent is directly or indirectly labeled with a detectable label, and the detectable label is selected from at least one of the following: a radioisotope, a fluorescent group, a chemiluminescent moiety, an enzyme, an enzyme substrate, an enzyme cofactor, an enzyme inhibitor, a dye, a metal ion or a ligand.

8. The product according to claim 7, characterized in that The kit includes at least one of a Western blot kit, an enzyme-linked immunosorbent assay kit, a radioimmunoassay kit, a radial immunodiffusion kit, a two-dimensional two-phase immunodiffusion kit, a rocket immunoelectrophoresis kit, an immunohistochemistry staining kit, an immunoprecipitation assay kit, a complement fixation assay kit, a fluorescence-activated cell sorting kit, an aptamer chip kit, a microarray kit, a protein chip kit, a qPCR kit or a flow cytometry kit.

9. The product according to any one of claims 3 to 8, characterized in that: The detection device is selected from at least one of the following: Detection equipment used for real-time quantitative reverse transcription PCR, biochip detection, Southern blotting, Northern blotting, in situ hybridization, immunofluorescence or immunohistochemistry.

10. A system for early diagnosis, risk assessment, immune status assessment, prognosis prediction and / or treatment regimen selection of a subject's sepsis-related disease, characterized in that: The system comprises: (1) a first device for collecting and / or receiving data on HLA-DOA levels in a sample from a subject; (2) a second device for analyzing the data to perform early diagnosis of sepsis-related diseases, risk assessment, immune status assessment, prognosis prediction and / or treatment regimen selection for the subject; Wherein, the first device comprises the product of claims 3-9; And / or, the analyzing comprises comparing the level of HLA-DOA in the sample with a reference value.

Citation Information

Cited By

  • Application of CCL18 in preparation of sepsis-related lung injury diagnosis and prognosis evaluation product

    CN120539429A

  • Biomarker HLA-DOA for sepsis-related diseases and use thereof

    WO2026017136A1